{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T13:27:09Z","timestamp":1772285229826,"version":"3.50.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T00:00:00Z","timestamp":1473811200000},"content-version":"vor","delay-in-days":349,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","derm.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.det.2015.05.013","type":"journal-article","created":{"date-parts":[[2015,8,29]],"date-time":"2015-08-29T16:44:26Z","timestamp":1440866666000},"page":"819-833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Practical Management of CD30+ Lymphoproliferative Disorders"],"prefix":"10.1016","volume":"33","author":[{"given":"Lauren C.","family":"Hughey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.det.2015.05.013_bib1","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","article-title":"Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment","volume":"95","author":"Bekkenk","year":"2000","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.det.2015.05.013_bib2","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.det.2015.05.013_bib3","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2011-05-351346","article-title":"EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma","volume":"118","author":"Kempf","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.det.2015.05.013_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1600-0560.2006.00560.x","article-title":"Detection of clonal rearrangement of T-cell receptor genes in the diagnosis of primary cutaneous CD30 lymphoproliferative disorders","volume":"33","author":"Greisser","year":"2006","journal-title":"J\u00a0Cutan Pathol"},{"issue":"5","key":"10.1016\/j.det.2015.05.013_bib5","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/bjd.12463","article-title":"Lymphomatoid papulosis type D: an aggressive histology for an indolent disease","volume":"169","author":"Bertolotti","year":"2013","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.det.2015.05.013_bib6","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/PAS.0b013e3181e75356","article-title":"A\u00a0variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases","volume":"34","author":"Saggini","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.det.2015.05.013_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PAS.0b013e3182648596","article-title":"Angioinvasive lymphomatoid papulosis: a new variant simulating aggressive lymphomas","volume":"37","author":"Kempf","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.det.2015.05.013_bib8","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1097\/DAD.0b013e3182943394","article-title":"Angioinvasive lymphomatoid papulosis: another case of a newly described variant","volume":"36","author":"Sharaf","year":"2014","journal-title":"Am J Dermatopathol"},{"issue":"5","key":"10.1016\/j.det.2015.05.013_bib9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jaad.2012.12.952","article-title":"Follicular lymphomatoid papulosis revisited: a study of 11 cases, with new histopathological findings","volume":"68","author":"Kempf","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.05.013_bib10","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1365-2133.1992.tb00106.x","article-title":"The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas","volume":"126","author":"Beljaards","year":"1992","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2015.05.013_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/1523-1747.ep12312548","article-title":"Lymphomatoid papulosis and associated cutaneous lymphoproliferative disorders exhibit a common clonal origin","volume":"105","author":"Wood","year":"1995","journal-title":"J\u00a0Invest Dermatol"},{"issue":"17","key":"10.1016\/j.det.2015.05.013_bib12","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1056\/NEJM199204233261704","article-title":"Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone","volume":"326","author":"Davis","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.det.2015.05.013_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/sder.2000.8333","article-title":"Lymphomatoid papulosis and anaplastic large cell lymphomas of the skin","volume":"19","author":"Drews","year":"2000","journal-title":"Semin Cutan Med Surg"},{"issue":"1","key":"10.1016\/j.det.2015.05.013_bib14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0190-9622(83)70011-3","article-title":"The clinicopathologic spectrum of lymphomatoid papulosis: study of 31 cases","volume":"8","author":"Sanchez","year":"1983","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.05.013_bib15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2133.1982.tb00529.x","article-title":"PUVA-treatment in lymphomatoid papulosis","volume":"107","author":"Wantzin","year":"1982","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.05.013_bib16","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jaad.2009.05.014","article-title":"Clinical, histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients","volume":"61","author":"de Souza","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"Suppl 3","key":"10.1016\/j.det.2015.05.013_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1468-3083.2012.04520.x","article-title":"Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review","volume":"26","author":"Archier","year":"2012","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.det.2015.05.013_bib18","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/1097-0142(19940601)73:11<2759::AID-CNCR2820731118>3.0.CO;2-C","article-title":"The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy follow-up study","volume":"73","author":"Stern","year":"1994","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.det.2015.05.013_bib19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-4632.2004.02186.x","article-title":"UVB phototherapy and skin cancer risk: a review of the literature","volume":"44","author":"Lee","year":"2005","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2015.05.013_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1440-0960.2008.00505.x","article-title":"Successful treatment of lymphomatoid papulosis with photodynamic therapy","volume":"50","author":"Rodrigues","year":"2009","journal-title":"Australas J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2015.05.013_bib21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1600-0781.2006.00214.x","article-title":"308-nm Excimer laser for the treatment of lymphomatoid papulosis and stage IA mycosis fungoides","volume":"22","author":"Kontos","year":"2006","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"1","key":"10.1016\/j.det.2015.05.013_bib22","first-page":"57","article-title":"Lymphomatoid papulosis treated with extracorporeal photochemotherapy","volume":"5","author":"Wollina","year":"1998","journal-title":"Oncol Rep"},{"issue":"3","key":"10.1016\/j.det.2015.05.013_bib23","first-page":"360","article-title":"Primary cutaneous anaplastic large cell lymphoma successfully treated with low-dose oral methotrexate","volume":"18","author":"Fujita","year":"2008","journal-title":"Eur J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2015.05.013_bib24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2340\/00015555-1692","article-title":"Successful treatment of primary cutaneous anaplastic large cell lymphoma with intralesional methotrexate therapy","volume":"94","author":"Yokoi","year":"2014","journal-title":"Acta Derm Venereol"},{"issue":"6 Suppl 1","key":"10.1016\/j.det.2015.05.013_bib25","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1590\/abd1806-4841.20131731","article-title":"Primary cutaneous anaplastic large-cell lymphoma \u2013 case report","volume":"88","author":"Oliveira","year":"2013","journal-title":"An Bras Dermatol"},{"issue":"2","key":"10.1016\/j.det.2015.05.013_bib26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/0974-2077.58525","article-title":"Primary cutaneous anaplastic large cell lymphoma arising from lymphomatoid papulosis, responding to low dose methotrexate","volume":"2","author":"Nandini","year":"2009","journal-title":"J\u00a0Cutan Aesthet Surg"},{"issue":"3","key":"10.1016\/j.det.2015.05.013_bib27","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0190-9622(96)90442-9","article-title":"Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders","volume":"34","author":"Vonderheid","year":"1996","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2015.05.013_bib28","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0190-9622(03)00470-5","article-title":"Topical methotrexate for lymphomatoid papulosis","volume":"49","author":"Bergstrom","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2015.05.013_bib29","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/archderm.139.5.624","article-title":"Phase 1\/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides","volume":"139","author":"Demierre","year":"2003","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.det.2015.05.013_bib30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000068451","article-title":"Bexarotene is a new treatment option for lymphomatoid papulosis","volume":"206","author":"Krathen","year":"2003","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.det.2015.05.013_bib31","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/1523-1747.ep12330845","article-title":"Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferon-gamma","volume":"107","author":"Yagi","year":"1996","journal-title":"J\u00a0Invest Dermatol"},{"issue":"7","key":"10.1016\/j.det.2015.05.013_bib32","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/1097-0142(20001001)89:7<1603::AID-CNCR26>3.0.CO;2-9","article-title":"Therapeutic use of interferon-alpha for lymphomatoid papulosis","volume":"89","author":"Schmuth","year":"2000","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.det.2015.05.013_bib33","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1200\/JCO.1992.10.1.170","article-title":"Lymphomatoid papulosis: response to treatment with recombinant interferon alfa-2b","volume":"10","author":"Proctor","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.det.2015.05.013_bib34","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archderm.138.9.1137","article-title":"Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod","volume":"138","author":"Suchin","year":"2002","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.det.2015.05.013_bib35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/CCO.0000000000000048","article-title":"Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma","volume":"26","author":"Huen","year":"2014","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"10.1016\/j.det.2015.05.013_bib36","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jaad.2005.05.035","article-title":"Treatment of lymphomatoid papulosis with imiquimod 5% cream","volume":"54","author":"Hughes","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.05.013_bib37","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0190-9622(03)02484-8","article-title":"CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma","volume":"49","author":"Liu","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2015.05.013_bib38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jaad.2003.12.028","article-title":"Management of multifocal primary cutaneous CD30 anaplastic large cell lymphoma","volume":"51","author":"Shehan","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.05.013_bib39","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1001\/archdermatol.2009.74","article-title":"Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome","volume":"145","author":"Woo","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.013_bib40","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1100\/tsw.2011.80","article-title":"Perils and pitfalls regarding differential diagnosis and treatment of primary cutaneous anaplastic large-cell lymphoma","volume":"11","author":"Diamantidis","year":"2011","journal-title":"ScientificWorldJournal"},{"issue":"6","key":"10.1016\/j.det.2015.05.013_bib41","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/0190-9622(93)70140-O","article-title":"Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment","volume":"28","author":"Willemze","year":"1993","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2015.05.013_bib42","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.ijrobp.2007.08.077","article-title":"Treatment of primary cutaneous CD30+ anaplastic large-cell lymphoma with radiation therapy","volume":"70","author":"Yu","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.det.2015.05.013_bib43","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00277-012-1610-3","article-title":"Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin","volume":"92","author":"Desai","year":"2013","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.det.2015.05.013_bib44","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.clml.2013.03.008","article-title":"Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports","volume":"13","author":"Broccoli","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.det.2015.05.013_bib45","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clml.2012.12.008","article-title":"CD30-positive cutaneous T-cell lymphoma and response to brentuximab vedotin: 2 illustrative cases","volume":"13","author":"Mody","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.det.2015.05.013_bib46","first-page":"29","article-title":"Periocular cutaneous anaplastic large cell lymphoma clearance with brentuximab vedotin","volume":"6","author":"Kaffenberger","year":"2013","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"2","key":"10.1016\/j.det.2015.05.013_bib47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2340\/00015555-1874","article-title":"Complete remission of refractory, ulcerated, primary cutaneous CD30+ anaplastic large cell lymphoma following brentuximab vedotin therapy","volume":"95","author":"Patsinakidis","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.det.2015.05.013_bib48","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjd.13337","article-title":"Dramatic efficacy of brentuximab vedotin in 2 patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression","volume":"172","author":"Saintes","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2015.05.013_bib49","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1001\/jamadermatol.2014.1629","article-title":"Brentuximab as a treatment for CD30+ mycosis fungoides and Sezary syndrome","volume":"151","author":"Mehra","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"21 suppl","key":"10.1016\/j.det.2015.05.013_bib50","article-title":"Phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders","volume":"122","author":"Duvic","year":"2013","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.det.2015.05.013_bib51","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1002\/cncr.28712","article-title":"Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project","volume":"120","author":"Carson","year":"2014","journal-title":"Cancer"},{"issue":"5 Suppl","key":"10.1016\/j.det.2015.05.013_bib52","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1016\/j.jaad.2005.11.1037","article-title":"Treatment of primary cutaneous CD30+ anaplastic large cell lymphoma with intralesional methotrexate","volume":"54","author":"Blume","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.det.2015.05.013_bib53","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/j.leukres.2011.06.029","article-title":"Primary cutaneous CD30 positive anaplastic large cell lymphoma \u2013 report of a case treated with bexarotene","volume":"35","author":"Oliveira","year":"2011","journal-title":"Leuk Res"},{"issue":"Suppl 1","key":"10.1016\/j.det.2015.05.013_bib54","first-page":"15","article-title":"Long-term bexarotene monotherapy in large cell CD30+ pleomorphic T-cell lymphoma","volume":"26","author":"Aldaoud","year":"2008","journal-title":"Dermatol Clin"},{"issue":"5","key":"10.1016\/j.det.2015.05.013_bib55","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/10428190290021425","article-title":"Response of CD30+ large cell lymphoma of skin to bexarotene","volume":"43","author":"Keun","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.det.2015.05.013_bib56","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/(SICI)1097-0142(19961015)78:8<1805::AID-CNCR23>3.0.CO;2-0","article-title":"Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki-1 anaplastic large cell lymphoma. Special emphasis on the tumor response to 13-cis retinoic acid","volume":"78","author":"Chou","year":"1996","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.det.2015.05.013_bib57","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00277-014-2121-1","article-title":"Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine","volume":"93","author":"Pellegrini","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.det.2015.05.013_bib58","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"issue":"5","key":"10.1016\/j.det.2015.05.013_bib59","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1111\/j.1365-2230.2008.03182.x","article-title":"Primary cutaneous CD30+ anaplastic large-cell lymphoma with generalized skin involvement and involvement of one peripheral lymph node, successfully treated with low-dose oral etoposide","volume":"34","author":"Yamane","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.05.013_bib60","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1067\/mjd.2001.117519","article-title":"Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy","volume":"45","author":"French","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2015.05.013_bib61","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1046\/j.0926-9959.2001.00293-8.x","article-title":"Primary cutaneous anaplastic large cell lymphoma in a young girl","volume":"15","author":"Hazneci","year":"2001","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.det.2015.05.013_bib62","first-page":"467","article-title":"Primary cutaneous CD30+ anaplastic large cell lymphoma responds to imiquimod cream","volume":"18","author":"Ehst","year":"2008","journal-title":"Eur J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.05.013_bib63","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/j.1365-2133.2004.05993.x","article-title":"Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara)","volume":"150","author":"Didona","year":"2004","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2015.05.013_bib64","first-page":"391","article-title":"Topical imiquimod as treatment for different kinds of cutaneous lymphoma","volume":"16","author":"Coors","year":"2006","journal-title":"Eur J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2015.05.013_bib65","first-page":"440","article-title":"Novel use of 308-nm excimer laser to treat a primary cutaneous CD30+ lymphoproliferative nodule","volume":"6","author":"Meisenheimer","year":"2007","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.det.2015.05.013_bib66","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2340\/0001555574206207","article-title":"In\u00a0vitro and in\u00a0vivo effects of photodynamic therapy in cutaneous T cell lymphoma","volume":"74","author":"Boehncke","year":"1994","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.det.2015.05.013_bib67","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/(SICI)1096-9101(1996)19:4<451::AID-LSM11>3.0.CO;2-5","article-title":"Comparison of sensitivity towards photodynamic therapy of cutaneous resident and infiltrating cell types in\u00a0vitro","volume":"19","author":"Boehncke","year":"1996","journal-title":"Lasers Surg Med"},{"issue":"5","key":"10.1016\/j.det.2015.05.013_bib68","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1751-1097.1995.tb02356.x","article-title":"The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor delta-aminolevulinic acid (ALA)","volume":"61","author":"Rittenhouse-Diakun","year":"1995","journal-title":"Photochem Photobiol"},{"issue":"1","key":"10.1016\/j.det.2015.05.013_bib69","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2230.2004.01448.x","article-title":"Photodynamic therapy may be useful in debulking cutaneous lymphoma prior to radiotherapy","volume":"29","author":"Umegaki","year":"2004","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"10.1016\/j.det.2015.05.013_bib70","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jaad.2011.12.011","article-title":"Recognizing large-cell transformation of mycosis fungoides","volume":"67","author":"Herrmann","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2015.05.013_bib71","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood-2008-05-154609","article-title":"Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation","volume":"112","author":"Arulogun","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.det.2015.05.013_bib72","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V92.4.1150","article-title":"Transformation of mycosis fungoides\/Sezary syndrome: clinical characteristics and prognosis","volume":"92","author":"Diamandidou","year":"1998","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.det.2015.05.013_bib73","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1200\/JCO.1995.13.7.1751","article-title":"Large-cell transformation following detection of minimal residual disease in cutaneous T-cell lymphoma: molecular and in situ analysis of a single neoplastic T-cell clone expressing the identical T-cell receptor","volume":"13","author":"Wolfe","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.det.2015.05.013_bib74","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/1523-1747.ep12389114","article-title":"Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides\/Sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR\/DGGE)","volume":"103","author":"Wood","year":"1994","journal-title":"J\u00a0Invest Dermatol"},{"issue":"31","key":"10.1016\/j.det.2015.05.013_bib75","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.det.2015.05.013_bib76","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","article-title":"Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"119","author":"Horwitz","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.det.2015.05.013_bib77","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.3109\/10428194.2013.779688","article-title":"Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy","volume":"54","author":"Koch","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"1\u20132","key":"10.1016\/j.det.2015.05.013_bib78","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000121002","article-title":"Treatment of transformed mycosis fungoides with intermittent low-dose gemcitabine","volume":"73","author":"Awar","year":"2007","journal-title":"Oncology"},{"issue":"6","key":"10.1016\/j.det.2015.05.013_bib79","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/archderm.144.6.727","article-title":"Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sezary syndrome","volume":"144","author":"Quereux","year":"2008","journal-title":"Arch Dermatol"},{"issue":"12","key":"10.1016\/j.det.2015.05.013_bib80","first-page":"1","article-title":"Clinical roundtable monograph. The management of aggressive T-cell lymphoma: a discussion on transformed mycosis fungoides","volume":"8","author":"Horwitz","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"issue":"29","key":"10.1016\/j.det.2015.05.013_bib81","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"32","key":"10.1016\/j.det.2015.05.013_bib82","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.det.2015.05.013_bib83","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1365-2133.2012.10905.x","article-title":"Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions","volume":"167","author":"Akilov","year":"2012","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2015.05.013_bib84","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1365-2133.2006.07672.x","article-title":"Folliculotropic mycosis fungoides with CD30+ large-cell transformation in a young woman: beneficial effect of bexarotene","volume":"156","author":"Mitteldorf","year":"2007","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2015.05.013_bib85","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjd.12690","article-title":"Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas","volume":"170","author":"de Masson","year":"2014","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2015.05.013_bib86","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.det.2015.05.013_bib87","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3324\/haematol.2013.098145","article-title":"Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas","volume":"99","author":"de Masson","year":"2014","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.det.2015.05.013_bib88","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","article-title":"Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome","volume":"28","author":"Duvic","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.det.2015.05.013_bib89","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clml.2014.01.010","article-title":"Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed\/refractory mycosis fungoides","volume":"14","author":"Talpur","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.det.2015.05.013_bib90","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1534734614534978","article-title":"A\u00a0CD30(-) transformed mycosis fungoides case responding very well to systemic bexarotene and methotrexate","volume":"13","author":"Zindanci","year":"2014","journal-title":"Int J Low Extrem Wounds"},{"issue":"2","key":"10.1016\/j.det.2015.05.013_bib91","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jaad.2013.09.007","article-title":"Large-cell transformation of mycosis fungoides - differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium","volume":"70","author":"Kadin","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"26","key":"10.1016\/j.det.2015.05.013_bib92","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A\u00a0randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N\u00a0Engl J Med"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515000583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515000583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T20:39:45Z","timestamp":1718051985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863515000583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0733863515000583"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2015.05.013","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical Management of CD30+ Lymphoproliferative Disorders","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2015.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}